New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
08:11 EDTADHDAlcobra completes patient recruitment in Phase III clinical trial of MDX
Alcobra announced that recruitment of patients has been completed in the company's Phase III clinical trial of Metadoxine Extended Release, or MDX, in adult ADHD patients. The study is a 300-patient, randomized, placebo-controlled trial conducted at 18 sites in the United States and 2 in Israel. Patients were randomized to receive either 1400 mg MDX or placebo over 6 weeks following a 2-week screening period. The primary endpoint is the Conners' Adult ADHD Rating Scale, or CAARS-INV, a widely accepted clinical measure of the presence and severity of ADHD symptoms. Secondary endpoints include the computerized TOVA, or Test of Variables of Attention, which was also used in the previous Phase 2 studies, as well as safety assessments and additional exploratory endpoints.
News For ADHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2015
10:23 EDTADHDAlcobra management to meet with Jefferies
Subscribe for More Information
September 21, 2015
08:45 EDTADHDOn The Fly: Pre-market Movers
HIGHER: Atmel (ATML), up 15% after agreeing to be acquired by Dialog Semiconductor in a deal valued at approximately $4.6B, or the equivalent of $10.42 per Atmel share... uniQure (QURE), up 12% after announcing topline results of one-year follow-up data from a Phase I/II clinical trial in four Sanfilippo B syndrome patients... lululemon (LULU), up 3% after the stock was upgraded to Overweight at Morgan Stanley... Alcobra (ADHD), up 15% after announcing that the FDA has granted Fast Track designation to Metadoxine Extended Release for the treatment of Fragile X Syndrome... Denbury Resources (DNR), up 5% after announcing that its board has decided to suspend the company's current 6.25c per share quarterly cash dividend and reinstated the ability for the company to repurchase shares under its previously authorized share repurchase program, which was suspended in late 2014... TherapeuticsMD (TXMD), up 4% after Jefferies analyst Chris Howerton more than doubled his price target for shares to $15 from $7, citing a positive view Vagicap in vulvovaginal atrophy. LOWER: GoPro (GPRO), down 4% after Barron's contended in an article this weekend that the stock may slip another 30% despite its recent pullback... Weatherford (WFT), down 7.7% after announcing the launch of concurrent underwritten public offerings of ordinary shares and mandatory exchangeable subordinated notes for an expected combined amount of $1B... ImmunoGen (IMGN), down 4.7% after Morgan Stanley downgraded the stock to Underweight, stating that consensus estimates for its key asset, IMGN 853, remain too optimistic on the potential success of an upcoming Phase II study.
08:06 EDTADHDAlcobra wins FDA fast track designation for Fragile X treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use